Venture&Growth
Location
Hayward (CA), USA
Zürich, Switzerland
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
US-based MedTech company providing a medical implant to patients suffering from osteoarthritis of the knee.
Moximed is commercializing the KineSpring®, a medical implant for patients suffering from osteoarthritis of the knee. Osteoarthritis is the most common form of arthritis and affects an estimated 150 million people worldwide. The KineSpring® is designed to unload excess weight on the knee. It is therefore suited for a growing population of patients that are too young to receive knee replacement surgery. To date, over 600 patients have received a KineSpring® implant.
After Gilde invested in Moximed, the company started to commercialize its products in Europe and established a multinational user-base. It has further initiated clinical studies for market registration in the US and optimized the implant, procedure and surgical instruments. Moximed is based in Hayward, California.
More Moximed news
James Leech Joins Moximed as Chief Financial and Strategy Officer
Gilde Healthcare company Moximed reports treatment of first commercial patients post FDA approval
Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis
Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study
Gilde Healthcare company Moximed raises $40 Million to advance world’s first Implantable Shock Absorber for Knee Osteoarthritis
Moximed Closes Oversubscribed $50MM Financing Round
Moximed: First Patient Treated in US Study of Atlas® System for Unicompartmental Knee Osteoarthritis
Moximed’s Atlas™ Knee System Improves Pain Scores and Returns Function to Pre-Arthroplasty Patients with Medial Knee Osteoarthritis
Moximed Announces CE Mark and First Commercial Use of Atlas Knee System
Moximed closes $33 million financing round
Moximed Completes Enrollment of KineSpring System US SOAR Study in Patients with Knee Osteoarthritis
Moximed Initiates US Clinical Study with KineSpring® System in Patients with Knee Osteoarthritis
Moximed’s Implantable Knee Spring Successfully Reduces Pain and Quickly Returns Normal Function
Gilde Healthcare Partners invests in Moximed, Inc.
Venture&Growth
Amphista Therapeutics
Amphista Therapeutics is a UK-based company creating first-class therapeutics to selectively degrade and remove disease-causing proteins by harnessing the body’s natural processes. It’s next generation targeted protein degradation TPD-based medicines leverage novel mechanisms that make use of a wider range
Venture&Growth
Alleviant Medical
Alleviant Medical is a clinical stage medical device company founded in 2017 that has developed a minimally invasive system to treat patients suffering from chronic heart failure who are symptomatic despite appropriate medical therapy. The company has conducted successful first
Venture&Growth
Spyglass Pharma
Spyglass Pharma was founded in 2019 and is based in Aliso Viejo, California. They are developing a drug delivery platform mounted on an intraocular lens to address mild-moderate glaucoma in patients undergoing cataract surgery. The lead asset utilizes a well-established
